Guggenheim Initiates Coverage on Cyclerion Therapeutics (NASDAQ:KRSA)

Investment analysts at Guggenheim began coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research report issued on Monday, Marketbeat reports. The firm set a “buy” rating and a $70.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 105.88% from the stock’s previous close.

Several other brokerages have also recently issued reports on KRSA. Stifel Nicolaus initiated coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating and a $43.00 price objective for the company. TD Cowen started coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating on the stock. Zacks Research raised shares of Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. Finally, UBS Group began coverage on shares of Cyclerion Therapeutics in a report on Friday, September 11th. They set a “buy” rating and a $55.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Cyclerion Therapeutics presently has an average rating of “Buy” and a consensus target price of $56.00.

Cyclerion Therapeutics Trading Up 10.3%

KRSA opened at $34.00 on Monday. Cyclerion Therapeutics has a 12 month low of $7.19 and a 12 month high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.